Tarsus Pharmaceuticals Valuation
Is TARS undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 0/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for TARS?
Other financial metrics that can be useful for relative valuation.
|What is TARS's n/a Ratio?|
Price to Sales Ratio vs Peers
How does TARS's PS Ratio compare to its peers?
|TARS PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
FULC Fulcrum Therapeutics
ESPR Esperion Therapeutics
OCUL Ocular Therapeutix
CARA Cara Therapeutics
TARS Tarsus Pharmaceuticals
Price-To-Sales vs Peers: TARS is expensive based on its Price-To-Sales Ratio (26.2x) compared to the peer average (13.1x).
Price to Earnings Ratio vs Industry
How does TARS's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?
Price-To-Sales vs Industry: TARS is expensive based on its Price-To-Sales Ratio (26.2x) compared to the US Pharmaceuticals industry average (2.8x)
Price to Sales Ratio vs Fair Ratio
What is TARS's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||26.2x|
|Fair PS Ratio||2.8x|
Price-To-Sales vs Fair Ratio: TARS is expensive based on its Price-To-Sales Ratio (26.2x) compared to the estimated Fair Price-To-Sales Ratio (2.8x).
Share Price vs Fair Value
What is the Fair Price of TARS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate TARS's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate TARS's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.